Lupin Limited — Updates, 04-07-2025: Press Release

Lupin has announced a board meeting to consider the financial results for the quarter and half-year. The company launched Ipratropium Bromide Nasal Solution (0.03% and 0.06%) in the U.S., bioequivalent to Boehringer Ingelheim’s Atrovent® Nasal Spray, which has annual sales of USD 63 million. This launch strengthens Lupin’s respiratory portfolio in the U.S., targeting symptomatic relief for allergic and common cold-related rhinorrhea in adults and children, enhancing its presence in a key market with a high-demand product.